Truist Financial’s Humacyte HUMA Stock Holding History

Truist Financial’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,282	Closed	-$74.2K	–	2805
2025 Q3	$74.2K	Buy	+16,282	New	+$31.9K	﹤0.01%	2643

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Truist Financial's HUMA Position: Q4 2025 in Review

Truist Financial sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 16,282 shares — an estimated $74.2K sold.

Truist Financial first reported a position in HUMA in Q3 2025 and held it in 1 quarter. The position peaked at $74.2K in Q3 2025. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

Truist Financial reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
Truist Financial sold 16,282 Humacyte shares in Q4 2025, an estimated $74.2K.
Truist Financial first reported a position in Humacyte in Q3 2025 and held it in 1 quarter.
Truist Financial's Humacyte position peaked at $74.2K in Q3 2025.
147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.